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Abstract
Homocysteine has emerged as a novel independent marker of risk for the development of
cardiovascular disease over the past three decades. Additionally, there is a graded mortality risk
associated with an elevated fasting plasma total homocysteine (tHcy). Metabolic syndrome (MS)
and type 2 diabetes mellitus (T2DM) are now considered to be a strong coronary heart disease
(CHD) risk enhancer and a CHD risk equivalent respectively. Hyperhomocysteinemia (HHcy) in
patients with MS and T2DM would be expected to share a similar prevalence to the general
population of five to seven percent and of even greater importance is: Declining glomerular
filtration and overt diabetic nephropathy is a major determinant of tHcy elevation in MS and T2DM.
There are multiple metabolic toxicities resulting in an excess of reactive oxygen species associated
with MS, T2DM, and the accelerated atherosclerosis (atheroscleropathy). HHcy is associated with
an increased risk of cardiovascular disease, and its individual role and how it interacts with the
other multiple toxicities are presented.
The water-soluble B vitamins (especially folate and cobalamin-vitamin B12) have been shown to
lower HHcy. The absence of the cystathionine beta synthase enzyme in human vascular cells
contributes to the importance of a dual role of folic acid in lowering tHcy through remethylation,
as well as, its action of being an electron and hydrogen donor to the essential cofactor
tetrahydrobiopterin. This folate shuttle facilitates the important recoupling of the uncoupled
endothelial nitric oxide synthase enzyme reaction and may restore the synthesis of the omnipotent
endothelial nitric oxide to the vasculature.
Introduction and background
Homocysteine (Hcy) is a nonessential sulfur-containing
amino acid and an intermediary metabolic product
derived from the demethylated essential amino acid
methionine (figure 1).
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Since its discovery in 1932 by the 1955 Nobel Prize recip-
ient Vincent DuVigneaud [1] and its association with pre-
mature arteriosclerotic (fibrotic) vascular disease
described by Kilmer McCully in 1969 [2], Hcy has
emerged as a novel marker of risk for cardiovascular
disease.
In the past decade Hcy has become widely accepted as a
novel risk marker associated with atherosclerotic cardio-
vascular disease (CVD) in the coronary, cerebral, and
peripheral vascular beds. Additionally, it has been deter-
mined that hyperhomocysteinemia (HHcy) is an inde-
pendent and a graded risk factor for the development of
CVD [3-13]. The current role of Hcy as a causative factor
still remains controversial and needs to be more fully
elucidated.
The important role of oxidative – redox stress and HHcy is
biologically plausible because Hcy promotes oxidant
injury to vascular cells (particularly the endothelium and
the eNOS enzyme reaction) through the auto-oxidation of
Hcy, formation of Hcy mixed disulfides, interaction of
Hcy thiolactones, and protein homocysteinylation [14-
16].
Oxidation of two Hcy molecules yields the oxidized
disulfide (homocystine), two protons (H+), and two elec-
trons (e-), while promoting the formation of reactive oxy-
gen species (ROS).
Homocysteine metabolism: methionine – folate cycle and the folate shuttle Figure 1
Homocysteine metabolism: methionine – folate cycle and the folate shuttle Hcy is an intermediate metabolic prod-
uct of methionine metabolism. Once methionine is demethylated, producing Hcy it can be further catabolized to cystathionine 
and cysteine via the transsulfuration pathway. This transsulfuration pathway is dependent on the cystathionine beta synthase 
enzyme (CBS) and vitamin B6. Human vascular cells lack the CBS enzyme and therefore the transsulfuration pathway is not 
present. In the remethylation cycle termed the Methionine – Folate Cycle, folic acid (folate) serves as the methyl donor to con-
vert Hcy to Methionine. This reaction is dependent on the Methionine Synthase (MS) enzyme and the cofactor vitamin B12. 
Folate serves not only as a methyl donor but also as hydrogen and an electron donor. This hydrogen and electron donation 
capability renders folate as a dual source for stabilization of the tetrahydrobiopterin (BH4) Cofactor of the endothelial nitric 
oxide synthase (eNOS) reaction producing the quintessential endothelial nitric oxide (eNO) and the additional function of 
being a local endothelial microenvironment antioxidant. These findings have led to the hypothesis of a Folate Shuttle phenome-
non. As can be seen there may exist a relative endogenous endothelial folate deficiency resulting in a toxic effect of Hcy accu-
mulation within endothelial cells as a result of this Folate Shuttle.
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Also, formation of mixed disulfides contributes to the
additional formation of ROS
Hcy-SH + R-SH ---- O2 -------→ Hcy-S-SR + H2O   → ROS
Hcy-SH + R1-S-S-R2 ← → R1-S-S-Hcy + R2-SH   → ROS
R = any organic compound in the plasma with a thiol
group (-SH) accessible to react with Hcy, such as proteins,
cysteine, glutathionine, gamma-glutamylcysteine, or
cystinylglycine.
Additionally, Hcy may undergo complicated rearrange-
ments to form Hcy thiolactone (a cyclic thioester), which
is chemically reactive and acylates free amino groups such
as the side-chain lysine groups in proteins. In the process
of forming homocysteinylated proteins further oxidative
stress develops and homocysteinylated proteins become
damaged and may lose their biological activity. This
results in the modification of proteins and in particular
the modification of low-density lipoproteins (LDL-cho-
lesterol), which contribute to their retention within the
intima and subsequent inflammatory foam cell formation
associated with atherogenesis.
Jakubowski has recently been able to demonstrate that
Hcy is now considered to be a protein amino acid in
humans. In areas of turbulent blood flow the formation of
Hcy-N-protein mediated by S-nitroso-Hcy may account
for the observation that atherosclerosis originates mostly
at branch points and flow dividers in arteries [17].
Recent controversial findings have been published in
regards to post percutaneous coronary angioplasty
(PTCA) restenosis, one trial has shown a decrease in rest-
enosis and major adverse events of death, nonfatal
myocardial infarction, and need for repeat revasculariza-
tion [18-20], while others have shown no significant
effect on the occurrence of restenosis [21-23].
A recent secondary prevention trial by Liem et al. [24] has
shown no effect in cardiovascular risk reduction within 2
and now 4 years treatment with low dose folic acid sup-
plementation in patients previously on statin therapy and
stable coronary artery disease.
Regardless of the current controversies regarding Hcy as
being an independent risk factor or merely a risk marker,
Hcy has definitely emerged as one of the novel-multifac-
torial substrates, which interacts with conventional CVD
risk factors of the atherosclerotic process [25,26].
Numerous ongoing clinical trials have yet to determine if
lowering Hcy by folic acid supplementation decrease the
risk of cardiovascular events or cardiovascular mortality
and these trials will be forthcoming within the next few
years (table 1).
An attempt to shed some new light on the Hcy – HHcy
story as it pertains to the metabolic syndrome (MS), pre-
diabetes (PD), and overt type 2 diabetes mellitus (T2DM)
and their association with the multiple metabolic toxici-
ties resulting in an increase of reactive oxygen species
(ROS) will be discussed.
Furthermore, an attempt to develop a hypothesis that
HHcy is a marker of oxidative and redox stress, as a result
of an endogenous folate shuttle, which results in a relative
endogenous endothelial folate deficiency due to a folate
shuttle phenomenon to preferentially run the endothelial
nitric oxide synthase (eNOS) reaction will be explored.
The lack of Hcy catabolic transsulfuration in human vas-
cular cells provides an even more important role for the
folate shuttle phenomenon in vascular cells. This would
result in a relative endogenous endothelial folate defi-
ciency to operate the remethylation pathway via the
methionine – folate cycle culminating in vascular cell
HHcy.
This folate shuttle phenomenon could also be operative
in hypertension and non-diabetic atherosclerosis due to
an associated uncoupling of the eNOS enzyme reaction
with decreased endothelial nitric oxide (eNO) production
and resultant endothelial cell dysfunction.
There are multiple clinical factors associated with HHcy
(table 2)), as well as, multiple damaging effects to the vas-
cular system (table 3). In MS, PD, and T2DM there are
multiple injurious stimuli to the endothelial cell (includ-
ing HHcy), and these substrate interactions result in accel-
erated atherosclerosis → atheroscleropathy (figure 2).
While the liver normally contains the full complement of
metabolic enzymes to handle HHcy through the remeth-
Auto-oxidation of homocysteine
2Hcy - SH O
Homocysteine
2
()
---- -- ------  +  + → HcyS - SHcy 2 H 2e +-
Homocystine: oxidized disulfide e
Superoxide
Hydroxyl radical
Hydrogen pero
Generating ROS
()
→
x xide
SH
AMP
O NH
Aminoacyl-tRNA Synthetase
Bound Hcy adenylate (Hcy~AMP)
Hcy thiolactone
2
S
O
NH2
-AMPNutrition Journal 2004, 3 http://www.nutritionj.com/content/3/1/4
Page 4 of 23
(page number not for citation purposes)
ylation and the transsulfuration catabolic metabolic path-
way, it is limited in human vascular cells. Vascular cells in
particular do not express cystathionine beta synthase
(CBS), the first enzyme of the hepatic transsulfuration
pathway; nor do they express the enzyme betaine homo-
cysteine methyltransferase (BHMT), which catalyzes the
alternate remethylation pathway in the liver using betaine
as a substrate [27,28].
Therefore in vascular cells, Hcy metabolism is limited to
the B12 – folate dependent remethylation pathway cata-
lyzed by methionine synthase of the methionine-folate
cycle. Thus, vascular cells and particularly endothelial
cells may be especially vulnerable to the higher levels of
circulating and endogenous Hcy found in patients with
HHcy.
This makes the endothelial cell and smooth muscle cells
quite vulnerable to the previously discussed oxidative
stress of HHcy. In the MS, PD, and overt T2DM this would
definitely result in an additive – synergistic effect to the
associated multiple metabolic toxicities and the elevated
substrates of the A-FLIGHT acronym (table 4).
These findings would help to explain the increased mor-
tality and cardiovascular disease associated with HHcy,
especially in T2DM [29-31]. In concluding this section it
is important to note that:
HHcy is associated with an increased risk of cardiovascu-
lar disease, especially in non-insulin-dependent diabetes
mellitus [8].
Reactive oxygen species: "toxic oxygen"
ROS consist primarily of the oxygen free radicals (super-
oxide [O2
•-], hydroxyl radical [-OH•-], peroxynitrite
[ONOO•-]), the potent oxidizing agents of the non-radical
family (peroxide [H2O2] and hypochlorous acid
[HCLO]), and the organic analogues, which include reac-
tive nitrogen species: specifically, peroxynitrite [ONOO•-]
(table 5).
It has been known for some time that ROS are detrimental
and toxic to cells and tissues as a result of injury to lipids,
nucleic acids, and proteins: (A). Lipid peroxidation of
membranes (loss of membrane function and increased
permeability) and generation of lipid autoperoxidation
reactions. (B). DNA damage leading to mutation and
death. (C). Cross linking or vulcanization of sulfhydryl
rich proteins (leading to stiff aged proteins specifically
collagen of the extracellular matrix) [32].
Both intracellular and extracellular antioxidants play
important roles in neutralizing these toxic oxygen
molecules. The endogenous antioxidant enzyme family
consists primarily of superoxide dismutase (SOD), cata-
lase, glutathione peroxidase and the tri-peptide (gamma-
L-glutamyl-L-cysteintyl-glycine) glutathione or (GSH),
and free circulating thiols containing the sulfhydryl group
(-SH) (table 6). These antioxidants are found to be sys-
temically depleted in the clinical setting of T2DM and evi-
dence is present for their depletion in atheromatous
lesions [31,32].
There are multiple metabolic toxicities associated with
MS, PD, T2DM, and their companion: accelerated athero-
sclerosis (atheroscleropathy). These multiple metabolic
toxicities can be conveniently grouped in an acronym
termed the A-FLIGHT toxicities (table 4). Each of these
toxicity substrates result in the excessive production of
ROS responsible for the damaging effects of oxidative –
redox stress.
Not only are ROS involved in the development of autoim-
mune type 1 diabetes mellitus and T2DM but also play an
important role in the long-term development of the asso-
ciated complications: atheroscleropathy, diabetic cardio-
myopathy, intimopathy, nephropathy, neuropathy,
endotheliopathy, and retinopathy.
Table 1: Homocysteine lowering intervention trials for the prevention of CVD.
1. SEARCH: Study of the effectiveness of additional reduction in cholesterol and homocysteine. University of Oxford, England.
2. PACIFIC: Prevention with a combined inhibitor of folate in coronary heart disease. University of Sydney, Australia.
3. WACS: Women's antioxidant and cardiovascular disease study. Harvard Medical School, USA.
4. CHAOS-2: Cambridge heart antioxidant study. University of Cambridge, England.
5. NORVITE: Norwegian study of homocysteine lowering with B-vitamins in myocardial infarction. University of Tromso, Norway.
6. BERGEN: Bergen vitamin study. University of Bergen, Norway.
7. HOPE-2: Health outcome and prevention evaluation number 2. Canada.
8. VISP: Vitamin intervention for stroke prevention. Wake Forest University, USA.
9. VITATOPS: Vitamins to prevent strokes. Perth, Australia.
10. IST-2: International strokes trial number 2. Auckland, New Zealand.Nutrition Journal 2004, 3 http://www.nutritionj.com/content/3/1/4
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Hyperhomocysteinemia and reactive oxygen species in 
insulin resistance, metabolic syndrome, type 2 diabetes 
mellitus, and atheroscleropathy
There are multiple metabolic toxicities associated with
MS, PD, and overt T2DM, which are associated with the
production of ROS. These toxic substrates and their asso-
ciated ROS have been conveniently grouped together to
form the acronym: A-FLIGHT toxicities (table 4).
The general population of patients with MS, IR, PD, and
overt T2DM will, in allprobability, have a similar fre-
quency of the common polymorphism affecting the
folate-dependent, thermolabile gene coding for the 5, 10-
methylene tetrahydrofolate reductase MTHFR) ((C677T,
Ala → Val) is associated with a decreased activity of the
enzyme with subsequent mild to moderate HHcy, which
occurs in 10–15% of the general population [33-35].
Multiple injurious stimuli to the endothelium, intima, media, and adventitia Figure 2
Multiple injurious stimuli to the endothelium, intima, media, and adventitia The endothelial cell is exposed to mul-
tiple injurious stimuli consisting of: modified LDL-cholesterol, various infection insults (viral and bacterial), angiotensin II, hemo-
dynamic stress, LPa, glucose, homocysteine, and intimal redox stress or reactive oxygen species. As discussed in this review, 
the toxicity of homocysteine may act alone as well as in concert with the other multiple injurious stimuli to injure the endothe-
lium resulting in endothelial cell dysfunction. Especially in the MS, PD, overt T2DM, and atheroscleropathy. It is of importance 
to note that native LDL-cholesterol is not atherogenic to the vascular intima. The process of oxidation, glycation, glycoxida-
tion, or homocysteinylation must modify LDL-cholesterol in order to become atherogenic. Thus, the importance of the multi-
ple injurious stimuli acting alone and synergistically to modify LDL-cholesterol and accelerate angiogenesis as seen in the 
accelerated atherosclerosis associated with MS, PD, and overt T2DM termed atheroscleropathy.Nutrition Journal 2004, 3 http://www.nutritionj.com/content/3/1/4
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This gene polymorphism is especially important in those
individuals with a decrease in dietary folate. In these
patients mild to moderate HHcy can be improved with
dietary and folate supplementation, which improves
endothelial-dependent endothelial cell dysfunction [36].
In the general population, mild to moderate HHcy occurs
in approximately 5–7% [9].
HHcy is not usually present as a direct result of MS, PD,
and T2DM unless there is an associated development of
impaired renal function. As nephropathy develops, there
is an associated elevation of total Hcy associated with a
decline in glomerular filtration rate [37].
In the early latent Stage I and transitional Stage II of T2DM
(table 7) homocysteine may actually be lower than
expected. Rosolova H et al. have found an unexpected
inverse relationship between IR and serum Hcy in a pop-
ulation of healthy subjects with insulin resistance. They
have attributed this finding to the associated increase in
the glomerular hyperfiltration [38].
IR and PD (Stages I, II, and early Stage III) are associated
for a period of time with hyperinsulinemia, hyperproin-
sulinemia, and hyperamylinemia and glomerular hyper-
filtration and hyperperfusion. Recently, the nitric oxide
system has been shown to be involved in glomerular
hyperfiltration in Japanese normo- and micro-albuminu-
Table 2: CLINICAL FACTORS ASSOCIATED WITH HHcy
1. Age and Gender: HHcy is associated with aging and male gender. Females typically have Hcy levels 20% 
lower than men until menopause. After menopause fasting levels of Hcy rise to those 
of men of similar age.
2. Genetic: Not only deficiency but also dysfunction 
secondary to various gene polymorphisms.
1. Cystathionine Beta Synthase deficiency.
2. 5,10-methylenetetrahydrofolate reductase deficiency.
3. Methionine synthase deficiency (including abnormalities in cobalamin metabolism).
4. Methylenetetrahydrofolate homocysteine methyltransferase deficiency.
3. Renal Function: Hcy levels increase with elevations of creatinine levels. Due to impaired renal 
excretion (decreased glomerular filtration rate) and or impaired metabolism.
4. Nutritional Status: Decreased vitamin cofactors (folate, vitamin B12, and B6). Aging – Alterations in gastric 
mucosa affecting intrinsic factor, inflammatory bowel diseases such as Crohn's disease 
and Ulcerative colitis, celiac disease, lymphomas and amyloidosis to name a few.
5. Disease States: Hypothyroidism. Carcinomas (breast, ovary, and pancreas in particular). Chronic 
renal failure from any cause especially diabetic and hypertensive nephropathy. 
Systemic lupus erythematous. Psoriasis. Solid organ transplantation. Malabsorption 
syndromes associated with nutritional status: Number 4.
6. Medications: Anticonvulsants, such as phenytonin, Methotrexate, Theophylline and other 
bronchodilaors of the phosphodiesterase inhibitor class, which interfere with 
pyridoxal phosphate synthesis. Nitrous oxide, L-dopa, Carbamazepine, Niacin, 
Fibrates, and Bile acid resins to name a few.
7. Endothelial Cell Dysfunction: Any cause for a 
decrease in eNOS enzyme or eNO bioavailability.
Any cause of endothelial cell dysfunction could result in HHcy if one accepts the 
endogenous endothelial folate shuttle HYPOTHESIS.
Table 3: DAMAGING EFFECTS OF HOMOCYSTEINE
1. Endothelial cell dysfunction. Decreased eNO bioavailability.
2. Endothelial cell toxicity – apoptosis.
3. Smooth muscle cell proliferation – myointimal hyperplasia and hypertrophy. Hcy induces Ca++ second messenger in vascular SMCs.
4. Extracellular matrix remodeling – activation of redox sensitive MMPs. Decreased bioavailability of eNO. Resulting in ECM fibrosis.
5. Promotes vasoconstriction
6. Promotes LDL-cholesterol modification: LDL-C – Homocysteine thiolactone aggregates.
7. Pro-inflammatory: MCP-1 and IL-8.
8. Promotes macrophage – foam cell formation via LDL-cholesterol modification.
9. Prothrombotic: Hcy reduces thrombomodulin and heparan sulfate levels. Decreases protein C activity and inhibits binding of tPA to endothelial 
cells. Hcy activates factors V and XII and increases tissue factor expression. Hcy induces platelet adhesiveness and aggregation.
10. Pro oxidative and redox stress via reactive oxygen species formation.
11. Induces 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase in endothelial cells.
12. Promotes oxidation of BH4 to BH2 and BH3, which uncouples the eNOS reaction resulting in superoxide formation and a decrease in eNO.
13. Promotes atherogenesis, arteriosclerosis, atherosclerosis, and atheroscleropathy.Nutrition Journal 2004, 3 http://www.nutritionj.com/content/3/1/4
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Table 4: MULTIPLE METABOLIC TOXICITIES IN MS AND T2DM: THE A-FLIGHT ACRONYM
Initiator Metabolic Defect Metabolic mediator Functional mediator Consequence
A AMYLIN (Co-secreted – Co-
packaged within the insulin secretory 
granule) by the islet Beta cell. 
Insulin's "Fraternal Twin" Elevated in 
MS, PD, and Early T2DM)
Hyperamylinemia Activation of ANG II PKC Signal Transduction 
Islet Amyloid IAPP Islet 
aggregation and deposition. 
Beta cell apoptosis – Beta 
cell defect.
ROS IAPP Amyloid in islets 
contributing to Beta Cell 
defect. Possible deposition 
in the intima, mesangium, 
neuronal unit, and 
myocardial. REMODELING
ANG II Via RAAS activation In MS, 
PD, and T2DM
Ang II Excess Ang II Excess Most potent 
stimulus for: Activation of 
Vascular membrane bound 
NAD(P)H Oxidase Enzyme
PKC Signal Transduction. 
Superoxide production. 
Uncoupling of the eNOS 
reaction. TGF beta-1 
activation
ROS NAD(P)H oxidase 
Derived Superoxide 
Myocardial, Renal, Intimal, 
Retinal, and Neuronal 
remodeling
AGE Advanced Glycation 
Endproducts AFE Advanced 
fructosylation endproducts
AGE / AFE See Glucotoxicity 
(G) RAGE activation Receptor 
for AGE
Protein Cross – linking / 
Dysfunction RAGE Receptor 
for AGE
Matrix Defects Signal 
Transduction Matrix Defects 
Signal Transduction
ROS Myocardial, Renal, 
Intimal, Retinal, Neuronal – 
Endoneurial Fibrosis
Advanced Lipoxidation Endproducts 
(ALE)
ALE Protein Cross – linking Matrix Defects Signal 
Transduction
ROS Matrix Remodeling
AntioxidantEnzymes: Antioxidant 
reserve compromised
Reduced – Dysfunctional 
eNOS, SOD, GPx, GSH, 
Catalase, and Vit. C.
Decreased NO Decreased NO REDOX 
STRESS
ROS REDOX STRESS
AntioxidantEnzymes: Absence of 
antioxidant network
IMPAIRED eNOS L-arginine 
BH4
Decreased NO Decreased NO ROS Decreased NO
AGING: Accumulation of multiple 
metabolic toxicities → ROS
Increased Ox-LDL-C, 
TNFalpha, Capase 3, 
Glomerulosclerosis.
Decreased NO: Decreased NO ROS Inflammation, 
Apoptosis
Atherosclerotic Nephropathy ROS beget ROS 
Atheroscleropathy
Decreased NO Self 
perpetuating Decreased NO
Decreased NO Athero – 
emboli Activated Platelets 
See Thrombotic Tox.
ROS beget ROS Decreased 
NO
F Free fatty acid toxicity Elevated FFA LC acyl -CoA's Mitochondrial Defects ROS Cytotoxicity
L Lipotoxicity Lipid Triad FFA ALE 
Long chain acyl-COA's
Increased VLDL – VLDL 
Triglycerides and Small dense 
atherogenic LDL-Cholesterol 
with Decreased HDL-
Cholesterol LIPID TRIAD
LC acyl -CoA's Fat 
Accumulation
Non Adipose Accumulation 
of Fat (LC acyl -CoA's) in 
Adipose and Non Adipose 
Tissue
ROS Accumulation of fat in 
non adipose tissues resulting 
in Ceramide induced: 
Cytotoxicity
I Insulin toxicity ENDOGENOUS 
Insulin Resistance
Hyperinsulinemia 
Hyperamylinemia in : MS, PD, 
EARLY T2DM Glut 4 is NO 
dependent Redox sensitive 
pathway
Ang II Increase # AT-1 
receptors Cross-talk with 
AT-1 Increase FFA Increase 
PAI-1 Increase Sympathetic 
tone and activity Increased 
Na+ and H2O reabsorption 
Increase Volume and Blood 
Pressure Hypertension Hype
NAD(P)H REDOX STRESS 
SIGNAL PATHWAYS PI3 
Kinase / Akt (Protein kinase 
B)→ MAP Kinase Shunt
ROS ROS ROS Extracellular 
Matrix Remodeling Islet, 
intimal, renal, myocardial, 
and neuronal.
Inflammation toxicity. "Inflammatory 
Cycle" (figure 5)
Activation of the innate 
immune system: IL-6, IL-8, 
TNF alpha Macrophage (MPO) 
→ Hypochlorous Acid 
Superoxide O2
•
Acute Phase Reactants: C-
Reactive Protein Serum 
Amyloid A Fibrinogen
NF kappa B Cellular 
Adhesion Molecules: ICAM, 
VCAM, and MCP-1
ROS Inflammation begets 
Inflammation " 
INFLAMMATORY CYCLE " 
(figure 5) ROS beget ROS
Insulin deficiency OVERT T2DM GLUCOTOXICITY 
POLYOL SORBITOL 
PATHWAY
REDUCTIVE STRESS 
NADH > NAD+ 
PSEUDOHYPOXIA
ROS
G Glucotoxicity Glycation / AGE See above See above See above
Protein inactivation Receptor-ligand defects Dysfunctional Signal 
Transduction
NO quenching Vasoconstriction Ischemia/Hypoxia ROS
Macrophage Activation Increased Cytokines, TGF-
Beta
Cytotoxicity ROS
Free Radical Formation REDOX STRESS Cytotoxicity ROS
Auto-oxidation Free Radical Formation REDOX STRESS Cytotoxicity ROS
ORIGIN OF REDUCTIVE STRESS ! 
REDUCTIVE STRESS !
Polyol Sorbitol Pathway (eNO 
inhibits Aldose Reductase)
Increased NADH Lactate 
Reductive Stress
REDOX STRESS Decreased 
NO Pseudohypoxia
Cytotoxicity ROS Ischemia/ 
Hypoxia
Decreased Taurine REDOX STRESS ROS Cytotoxicity
Increased DAG Increased PKC Signal Transduction Ischemia ROS
Glucotoxicity Glucotoxicity Polyol – Sorbitol Pathway PAS + material Interstitium, 
Basement Membrane
Remodeling – 
Cardiomyopathy CHF 
Diastolic Dysfunction
H Hypertension Toxicity 
Homocysteine Toxicity
RAAS activation HHcy NO 
quenching and NEW: PPAR 
interaction.
Ang II Decreased GPx, 
DDAH with resultant ^ 
ADMA
NAD(P)H REDOX STRESS 
^ ROS, O2', ONOO', 
nitrotyrosine
ROS Decreased NO, 
Endothelial Cell toxicity, 
dysfunction, and apoptosis
T Triglyceride Toxicity Thrombotic 
Toxicity Taurine (antioxidant) 
depletion
Triglyceride – FFA exchange See FFA – Lipotoxicity above 
eNOS uncoupling
REDOX STRESS Activated 
Platelets PAI-1 elevation 
Fibrinogen elevated. 
Decreased NO
ROS Athero-emboli ROSNutrition Journal 2004, 3 http://www.nutritionj.com/content/3/1/4
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ric patients with T2DM and early stages of diabetic
nephropathy [39]. Hiragushi K et al. were able to demon-
strate an increase staining of eNOS enzyme (in glomerular
endothelial cells) in microalbuminuric T2DM patients in
comparison to non-diabetic control subjects.
This adaptive early response results in glomerular enlarge-
ment and an increase in the glomerular filtration rate [40].
Additionally, Apakkan Aksun S et al. found that serum
and urine nitric oxide levels were elevated, as well as,
plasma malanodialdehyde (MDA), which points to the
importance of oxidative stress in patients with T2DM.
These authors feel that the high nitric oxide levels may
lead to hyperfiltration and hyperperfusion, which in turn
leads to an increase in urinary albumin excretion and thus
causes progression of nephropathy in early T2DM [41].
Over time (Stages III-V, table 7) there is an increase in glu-
cotoxicity (initially postprandial Stage III and fasting in
Stage IV), as well as, an increase in redox and oxidative
stress to the glomerular endothelium. This damage is
associated with lipid peroxides, free fatty acids, and activa-
tion of Ang II as a result of hyperinsulinemia, hyperproin-
sulinemia, hyperamylinemia and the totality of reactive
oxygen species associated with the A-FLIGHT toxicities.
The activation of Ang II would be associated with the acti-
vation of the membranous NAD(P)H oxidase enzyme and
generation of superoxide with its effect on endothelial cell
dysfunction and uncoupling of the eNOS reaction. Over
time, this would result in decreases in eNO and loss of a
natural occurring local antioxidant network within the
glomerular endothelial microenvironment.
Table 5: Origin, enzymatic pathways of reactive oxygen species, and their oxidized products.
Origin – Location Enzymatic Pathway ROS Potent Oxidants PRODUCTS Oxidized lipids and Proteins
Mitochondrial Respiratory Chain O2
• -OH• Oxidized lipids, proteins, nucleic acids, and autoxidation 
byproducts.
Inflammatory Macrophage Membraneous NAD(P)H 
Oxidase
O2
• OH• H2O2 Advanced Lipoxidation Endproducts (ALE) Ortho o-tyrosine 
Meta m- tyrosine
Granular Myeloperoxidase (MPO) Hypochlorous Acid HOCL (bleach) •Tyr NO2
• 3-Chlorotyrosine di-Tyrosine NO2-Tyrosine (Nitrotyrosine)
Macrophage Nitric Oxide Synthase (NOS) Inducible 
(iNOS) Large bursts uncontrolled
ONOO' NO2-Tyr (Nitrotyrosine)
Endothelial Cell
Nitric Oxide Synthase (NOS) Constitutive (cNOS) eNOS 
→ NO nNOS → NO Small bursts (puffs) controlled
NO + O2• → ONOO' ONOO' NO2-Tyr (Nitrotyrosine) NO2-Tyr
eNOS derived NO NO: the GOOD Natural Occurring, Local Occurring, Chain Breaking 
Antioxidant
Superoxide O2
.: the BAD
Peroxynitrite ONOO• : the UGLY
Hypochlorous acid HCLO : the UGLY
Restoration of endothelial derived NITRIC OXIDE Via the 
eNOS reaction..
ANTIOXIDANT ANTIREDOXIDANT → → 
→
Prevention of the devastating effects of ROS.
Table 6: Antioxidants: catalytic – enzymatic inactivation of free radicals.
Enzymatic Antioxidants
SUPER OXIDE DISMUTASE (SOD)[O2
- + SOD → H2O2 + O2] ecSOD (extracellular) MnSOD (mitochondrial) CuZnSOD (intracellular)
CATALASE– Location: peroxisome [2H2O2 + catalase → 2 H2O + O2]
GLUTATHIONE PEROXIDASE– Location: mitochondrion – cytosol and systemic circulation. (Glutamyl-cysteinyl-glycine tripeptide) 
glutathione reduced -SH to the oxidized disulfide GSSG. (Glutathione peroxidase) [GSH + 2H2O2 → GSSG + H2O + O2] (Glutathione reductase) 
[GSSG → GSH] at the expense of [NADH → NAD+] and/or [NAD(P)H → NAD(P)+]
NOS (nitric oxide synthase).– Location: membrane Isoforms: (e)NOS (endothelial): good (n)NOS (neuronal): good (i)NOS (inducible-
inflammatory): bad
O2
- and nitric oxide (NO) are consumed in this process with the creation of reactive nitrogen species (RNS). O2
- + NO → ONOO- (peroxynitrite) 
+ tyrosine → nitrotyrosine. Nitrotyrosine reflects redox stress and leaves a measurable footprint. NO: the good; O2
-: the bad; ONOO-: the ugly 
[42]
Nonenzymatic Antioxidants
URIC ACID
VITAMIN A, VITAMINC, andVITAMINE
THIOLS: Sulfhydryl (-SH) containing molecules.
ALBUMIN: Is an antioxidant due to thiol containing compounds.
APOPROTEINS: Ceruloplasmin and transferrin. Bind copper and iron in forms which cannot participate in the Fenton reactionNutrition Journal 2004, 3 http://www.nutritionj.com/content/3/1/4
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Glucotoxicity is associated with advanced glycosylation
endproducts (AGEs) and their receptor (RAGE), activa-
tion of aldose reductase of the polyol-sorbitol pathway,
activation of protein kinase C (PKC) isoforms, and
transforming growth factor beta (TGFbeta). Once these
glucotoxic mechanisms are in play and overt diabetic
nephropathy with associated glomerulosclerosis and
remodeling has developed, there will be a progressive
decrease in glomerular filtration. These changes will result
in Hcy elevation [37].
Thus, HHcy plays an extremely important role for addi-
tional oxidative-redox stress regarding the accelerated car-
diovascular disease observed in diabetic patients on
dialysis [42].
HHcy is thought to induce an oxidative inactivation of
endothelial nitric oxide, in part by inhibiting or consum-
ing the expression of cellular glutathione peroxidase
(GPx). In heterozygous cystathionine beta-synthase defi-
cient -/+ mice, Weiss et al. were able to restore endothelial
cell function by increasing cellular thiols and reduced glu-
tathione pools and increasing GPx activity with restora-
tion of the endothelial function [43].
The ensuing cellular redox stress is magnified and total
Hcy consumes NO by the indirect process of superoxide
(O2
-) converting NO to toxic peroxynitrite (ONOO-).
In addition to ONOO- formation, NO in conjunction
with thiols and oxygen radicals generate nitrotyrosine and
nitroarginine. Nitroarginine, in turn, competes for the
substrate L-arginine of the eNOS reaction in a feedback
mechanism, limiting further NO generation [44-46]. As a
result, there is endothelial cell dysfunction, endothelial
cell toxicity and endothelial cell loss-apoptosis, increased
ROS, increased ONOO- and decreased NO associated with
HHcy [47]. HHcy is multiplicative in nature and even
though its effects may occur later in T2DM than the other
associated A-FLIGHT substrate toxicities, it has a devastat-
ing – synergistic effect on endothelial cell function. Pres-
ently, we know there are other multiple metabolic
toxicities (table 4) operating within the renal glomerulus
producing microalbuminuria (reflecting endothelial cell
Table 7: The Five Stages of T2DM:
The Natural Progressive History of T2DM.
I. LATENT STAGE:[EARLY]
Insulin Resistance:
Genetic Component
Environmental component. Modifiable: obesity/sedentary life style. Nonmodifiable: aging
Beta Cell Defect: (Dysfunction)
Genetic ....... Abnormal processing, storage or secretion.
Intracellular/extracellular oligomers of Islet Amyloid toxicity to the Beta Cell. Abnormal processing, storage or secretion
Islet Amyloid: Diffusion Barrier: Secretory Defect: Intra Islet Absorptive Defect:
II. TRANSITION STAGE:[MIDDLE]
Persistent Hyperinsulinemia, Hyperproinsulinemia. → Ang II Accelerated Atherosclerosis
Persistent Hyperamylanemia. → AngII Accelerated Atherosclerosis
Continued remodeling of the endocrine pancreas (amyloid).
Beta cell displacement, dysfunction, mass reduction due to the toxic effect of IAPP oligomers and the progressive developing diffusion 
barrier.
III. IGT STAGE (Impaired Glucose Tolerance):[LATE] "Pre-diabetes" Human Health Services (HHS) and American Diabetes 
Association (ADA) term.
[Start treatment at this time]
Diagnose earlier: rejuvenation of the 2 hour glucose tolerance blood sugar 140–199 mg/dl
Increased insulin resistance [Feeds forward] > Glucotoxicity [Feeds forward] > Insulin resistance [Feeds forward] > Glucotoxicity: 
creating a vicious cycle.
Islet amyloid. Increasing beta cell defect. Loss of beta cell mass with displacement. (Remodeling of islet architecture including extracellular 
matrix). Beta cell loss centrally.
IV. IFG STAGE (Impaired Fasting Glucose):[LATER] "Pre-diabetes" Human Health Services (HHS) and American Diabetes Association 
(ADA) term.
Blood sugar ranging [110–125 mg/dL]
*ADA new cut point IFG Nov 2003: [100–125 mg/dl]
Impaired hepatic glucose production: Increasing global insulin resistance (hepatic) with subsequent gluconeogenesis. Feeding 
forward in the vicious cycle to accelerate insulin resistance globally.
V. OVERT STAGE:[TOO LATE] FBG 126 or greater: Random or 2 hour OGTT 200 or >
[50% loss of beta cell function at the time of clinical diagnosis]
Use medications that do not increase endogenous insulin or amylin. Use combination therapy. Start treatment at stage III-IV (IGT-IFG).
. Paradigm Shift. → Diagnose Early → Start treatment Early → Stage III: IGT.Nutrition Journal 2004, 3 http://www.nutritionj.com/content/3/1/4
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dysfunction and damage) at a stage prior to the declining
glomerular filtration rate responsible for HHcy (figure 2).
A recent clinical study by Maejima et al. [48] revealed sig-
nificant elevated levels of ONOO- peroxynitrite (by Griess
method) in 129 T2DM patients as compared to 76 non-
diabetic controls. While there was no difference in basal
plasma NO(2)(-) levels between the T2DM and control
patients, ONOO- levels were related to the presence of
hypertension and advanced microvascular complications.
In addition, ONOO- correlated positively with elevations
in AGEs and serum lipid peroxide. These data support the
hypothesis that decreased endothelium-dependent
vasodilatation in diabetic subjects is associated with the
impaired action of NO secondary to its consumption
(quenching) from redox stress rather than decreased NO
production from vascular endothelium. Clinically, abnor-
mal NO metabolism is related to advanced diabetic
microvascular complications.
Zhang et al. [49] were able to demonstrate that increased
concentrations of Hcy resulted in a decreased NO
response to bradykinin and L-arginine. Hcy stimulated
the formation of superoxide anions and peroxynitrite
with increased levels of nitrotyrosine. The addition of 5-
methyltetrahydrofolate (folic acid) restored NO responses
to bradykinin and L-arginine agonists. In addition, scav-
engers of peroxynitrite and SOD mimetics reversed the
Hcy-induced suppression of NO production by endothe-
lial cells. Concentrations of Hcy (greater than 20 micro-
molar concentration) produced a significant indirect
suppression of eNOS activity without any discernible
effects on its expression.
Li et al. just published an article showing an unexpected
effect of Hcy-induced oxidative stress resulting in an
increase of 3-hydroxy-3-methylglutaryl coenzyme A
reductase in vascular endothelial cells, as well as decreas-
ing endothelial NO. They were also able to demonstrate
that "statins" increased NO as well as decreasing cellular
cholesterol [50].
Stuhlinger et al were able to demonstrate that Hcy impairs
the nitric oxide synthase pathway. Homocysteine inhibits
dimethylarginine dimethylaminohydrolase (DDAH),
which is responsible for degrading ADMA. This effect of
Hcy causes the endogenous inhibitor of nitric oxide syn-
thase, ADMA, to accumulate and compete with L-arginine
for nitric oxide production. This effect helps to explain the
deleterious effect of Hcy on the endothelial cells ability to
promote vasodilatation and associated endothelial cell
dysfunction with decreased NO synthesis [51].
Previous publications have emphasized the importance of
the eNOS enzyme and the important role of the Glu298 →
Asp gene polymorphism [32,52]. Noiri and colleagues
have recently demonstrated that the gene polymorphism
(Glu298 → Asp) affecting the eNOS enzyme is statistically
and significantly associated with diabetic nephropathy in
T2DM patients [53]. This finding points to the important
role of the eNOS enzyme and eNO in controlling oxida-
tive – redox stress and its relation to the development of
diabetic nephropathy.
This same gene polymorphism (Glu298 → Asp) of the
eNOS enzyme (eNOS 894TT genotype) has also been
recently demonstrated to be a risk factor for HHcy. These
findings by Brown et al. indicate that the NOS3 894TT
genotype (eNOS Glu298 → Asp gene polymorphism) is a
risk factor for HHcy in healthy nonsmoking adults with
low serum folate and supports the hypothesis that nitric
oxide modulates Hcy through an effect on folate catabo-
lism [54].
Accelerated atherosclerosis → atheroscleropathy
The above discussion also applies to the accelerated
atherosclerosis (atheroscleropathy) and intimal redox
stress and remodeling (intimopathy) associated with MS,
PD, and overt T2DM [32].
Insulin resistance is central to the development of CHD
and the accelerated atheroscleropathy associated with MS,
PD, and overt T2DM. This being said, the ultimate mani-
festation of insulin resistance is T2DM [32] (figure 3).
Atherosclerosis, MS, PD, and T2DM present a pleiotropic
mechanistic progression, in which, inflammation and
upstream oxidative-redox stress and ROS appear to share
a common – fertile soil background, and patients with
diabetes experience both a preexisting and parallel-accel-
erated atherosclerosis, we have termed atheroscleropathy
[32,52,55] (figure 4).
In regards to silent coronary artery disease (CAD), Gazza-
ruso C et al. were able to confirm that microalbuminuria
and smoking may predict silent CAD in people with dia-
betes and additionally they were able to demonstrate an
original finding of an independent association between
HHcy and silent CAD [56].
In the Framingham offspring study [57], those with
hyperinsulinemia had significantly higher Hcy levels than
those without, and subjects with more than two MS
phenotypes (hypertension, impaired glucose tolerance, or
a central MS [consisting of two or more of the following:
hyperinsulinemia, obesity, or dyslipidemia]) had signifi-
cantly higher Hcy levels compared to those with one or no
MS phenotype.Nutrition Journal 2004, 3 http://www.nutritionj.com/content/3/1/4
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Passaro and colleagues have been able to demonstrate in
T2DM patients that Hcy levels are influenced by both the
duration of the disease and metabolic control. Hcy levels
improve with improvement of glycemic control of HbA1c.
Hcy remained strongly associated to the presence of CHD
independent from age, sex, body mass index, smoking sta-
tus, hypertension and lipid patterns. Additionally, they
conclude that Hcy can be seen as a major risk factor in
T2DM patients with CHD [58,59].
The initial vascular lesions described by McCully in 1969
[2] described an arteriosclerotic fibrotic change within the
intima, which is in contrast to the intimal fibrous-lipid
laden lesions associated with atherosclerosis and the vul-
nerable thin-cap fibroatheroma prone to rupture.
Burke and colleagues have been the first to describe the
plaque morphology and correlate these findings to total
plasma homocysteine [60]. Their recent publication dem-
onstrated that Hcy is elevated in sudden unexpected death
in men as a result of severe coronary artery disease with-
out acute or organized coronary thrombosis. Addition-
ally, they were able to demonstrate that the above
association seemed to be increased if there existed con-
comitant diabetes mellitus. HHcy was associated with an
increase in fibrous plaques and a relative decrease in thin-
cap atheromas. Their findings suggest a different mecha-
nism of atherogenesis from that of hypercholesterolemia.
Additionally, efforts to reduce Hcy could be complemen-
tary to lipid lowering therapy because plaque fibrosis may
occur via a distinct mechanism. They suggest that one
The metabolic syndrome: Syndrome X "reloaded" Figure 3
The metabolic syndrome: Syndrome X "reloaded" Metabolic syndrome (Syndrome X "reloaded") is a unique clustering 
of clinical syndromes and metabolic derangements. Reaven initially described the MS in 1988. He initially discussed the four 
major determinants consisting of: I. Hypertension. II. Hyperinsulinemia. III. Hyperlipidemia (Dyslipidemia of elevated VLDL – 
triglycerides, decreased HDL-cholesterol, and elevated small dense atherogenic LDL-cholesterol). IV. Hyperglycemia or glu-
cose intolerance. He also emphasized the importance of insulin resistance being central to the development of coronary artery 
disease or CHD. Since that time numerous papers and authors have added several associated findings to the MS and addition-
ally several other names have been given to describe this clustering phenomenon. The important association of polycystic 
ovary syndrome (PCOS), hyperuricemia, fibrinogen, hsCRP, microalbuminuria, PAI-1, and the more recently added asymmetri-
cal dimethyl arginine (ADMA), reactive oxygen species (ROS) and now the damaging oxidative potential of Hcy and endothelial 
dysfunction have all contributed to a better understanding of this complicated clustering phenomenon. The red boxes (ROS, 
Hcy, ADMA, and hsCRP) indicate the newer additions giving rise to the new terminology: Metabolic Syndrome Reloaded.
12/17/03 103 Hyperinsulinemia
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such mechanism could be endothelial dysfunction, which
certainly points to the importance of the "Folate Shuttle
phenomenon" within the endothelial cell and a relative
endogenous endothelial folate deficiency within the
endothelial microenvironment milieu.
These morphological findings suggest the need for; and
importance of; global risk reduction of the entire spec-
trum of elevated substrates within the A-FLIGHT multiple
metabolic toxicities.
PPAR and homocysteine
Peroxisome proliferator activated receptors (PPARs) are
transcription factors belonging to the nuclear receptor
super-family and the multiple roles of their effects are rap-
idly unfolding.
Clinically there are two classes of drugs currently in use:
fibrates binding to PPAR alpha (gemfibrozil and fenofi-
brate) and thiazolidinediones (TZDs) binding primarily
to PPAR gamma (rosiglitazone and pioglitazone). PPAR
alpha agonists are responsible primarily for their hypolip-
idemic effect, while PPAR gamma agonists are antidia-
betic agents – insulin sensitizers (enhancing insulin –
mediated glucose uptake and lowering of HbA1C), impor-
tant in the regulation of the lipid metabolism and adipo-
genesis, and additionally expressed in the vasculature
(endothelial cells, smooth muscle cells, and monocyte –
macrophage cells). In vitro and clinical data show that
TZDs can decrease thrombotic, inflammatory, and oxida-
tive changes that contribute to endothelial dysfunction
and their future vaculoprotective roles (table 8) in attenu-
ating the progressive role of non-diabetic atherosclerosis
The reactive oxygen species – inflammatory cycle: ROS are upstream from the inflammatory cycle Figure 4
The reactive oxygen species – inflammatory cycle: ROS are upstream from the inflammatory cycle Inflammation 
in MS, PD, overt T2DM, and atheroscleropathy has recently emerged as an important factor. While it has been interesting to 
observe the development of this exciting story, it is important to remember that reactive oxygen species (ROS) cycle occurs 
upstream from the inflammatory cycle via the redox sensitive nuclear transcription factor: NF kappa B and the resulting inflam-
matory markers: Selectins, cellular adhesion molecules, monocyte chemoattractant protein - 1, and the cytokines: TNF alpha, 
IL-6, IL-8 and the newer clinical laboratory tool of the highly sensitive C-reactive protein (hsCRP).
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and the accelerated atherosclerosis in MS, PD, and overt
T2DM [61-67].
Current available information suggests that PPAR-gamma
ligands may prevent the progression of insulin resistance
(preserving islet Beta cell function) to diabetes and
endothelial dysfunction to atherosclerosis [68].
Recently, Fonseca V. et al. were able to demonstrate that
the PPAR agonist troglitazone had a significant Hcy low-
ering effect in both the lean and fatty Zucker rat model of
insulin resistance. This decline in Hcy was associated with
significant increases in hepatic concentrations of S-adeno-
sylhomocysteine (SAH) and S-adenosylmethionine
(SAM) plus SAH. Additionally, there was a significant
decline in the SAM/SAH ratio. The hepatic CBS was signif-
icantly higher in the troglitazone treated group as com-
pared to the control group. The authors conclude that the
Hcy lowering effect of troglitazone may be due to a shift
in the concentrations of Hcy from the blood to the liver,
as well as, a possible upregulation of hepatic CBS [69].
Tao et al. just published a timely article that ties together
quite nicely the detrimental role of oxidative-redox stress
and ROS and the antioxidant, antinitrative, and
vasculoprotective role of PPARs. They were able to dem-
onstrate (in hypercholesterolemic rabbits) that treatment
with the PPAR gamma agonist rosiglitazone enhanced
PPARgamma expression, improved endothelium-depend-
ent vasodilatation, preserved the phosphorylation of
vasodilator-stimulated phosphoprotein (P-VASP),
suppressed gp91(phox) of the NAD(P)H Oxidase enzyme
and iNOS expression, reduced superoxide and total NOx
production, and inhibited nitrotyrosine formation [70].
Even though Hcy levels were not part of this publication,
a reasonable assumption would be that rosiglitazone
could also lower Hcy levels.
Recently, we have been able to demonstrate an important
finding regarding the interactions of Hcy with PPAR alpha
and gamma receptors. In addition to demonstrating that
HHcy decreases bioavailability of eNO, generates
nitrotyrosine, and activates latent matrix metalloprotein-
ase (which instigates endomyocardial endothelial fibrosis
and dysfunction) in vivo, we have been able to demon-
strate that Hcy acts in a competitive manner with the
PPAR receptor (in endomyocardial endothelial cells of
mouse myocardium) in vitro. Specifically, Hcy interacts
with the fibric acid PPAR alpha agonist ciprofibrate and
the PPAR gamma agonist 15-deoxy-Delta(12,14)-prostag-
landin J(2) (15d-PGJ2) [71-74].
This may have definite clinical applications regarding the
actions of the PPAR agonist family of fibric acid, as well as
the PPAR agonists: TDZs (rosiglitazone and pioglitazone
currently in clinical use). If Hcy is elevated there may exist
a competitive inhibition of the agonist effects of both of
these clinically useful medications (figure 5).
These findings of the potential interaction of Hcy with the
PPAR ligands may interfere with the positive role of glu-
cose -lipid regulation and anti-inflammatory
Table 8: POSITIVE EFFECTS OF PPARalpha AND PPARgamma AGONISTS
PPAR alpha: Lipid Effects
a). Primarily a VLDL-Cholesterol (triglyceride) by increasing lipoprotein lipase and secondary LDL-Cholesterol lowering.
b). HDL-cholesterol raising effect by increasing the expression of apo A-I and apo A-II. Positive outcomes of the Fibric acid (Gemfibrozil) (VA-
HIT) and Fenofibrate (DAIS) studies.
PPAR gamma effects:
a). Primary Clinical Action : (Insulin Sensitizers). Improving insulin mediated glucose uptake.
b). Decrease thrombotic, inflammatory and oxidative changes that contribute to endothelial cell dysfunction.
c). Improve vascular reactivity.
d). Decrease plasminogen activator inhibitor-1 (PAI-1).
e). Decrease moncyte expression NFkappa-B.
f). Anti-inflammatory effects: Inhibition of macrophage activation and the production of inflammatory cytokines (TNFalpha, interleukin 6 and 1beta). 
New findings: May be through the effects of PPARdelta.
g). Decrease C-reactive protein and IL-6 (both markers of inflammation and cardiovascular risk). Dandonna P reference. Diabetes Technol Ther. 
2002; 4(6): 809–15.
h). Inhibit vascular SMC migration and proliferation.
i). Lower blood pressure.
j). Attenuate myocardial hypertrophy and protect against ischemia-reperfuion injury.
k). Preserve pancreatic islet Beta cell function.
l). Attenuate (specifically rosiglitazone) oxidative and nitrative stress: enhanced PPAR gamma expression, improved endothelium – dependent 
vasodilation, preserved P-VASP, suppressed gp91(phox) of the membranous NAD(P)H Oxidase enzyme, reduced superoxide and total NOx (stable 
metabolic byproducts of NO) production, and inhibited nitrotyrosine formation.
m). Increase levels of Adiponectin.Nutrition Journal 2004, 3 http://www.nutritionj.com/content/3/1/4
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antiatherosclerotic actions of the fibric acid derivatives
and thiazolidinediones.
Homocysteine – folate – cobalamin triad and 
atherogenesis
Flynn MA et al. have discussed atherogenesis and the
Homocysteine-Folate-Cobalamin (HFC) Triad and it
seems pertinent to expand each of their respective roles in
this discussion [75].
The toxic role of Hcy on the vasculature has been exten-
sively discussed previously, however, the important role
of folic acid and cobalamin (vitamin B12) needs further
development.
Folic acid and the folate shuttle
Folic acid, the water soluble B vitamin (Vitamin B9), 5-
methyltetrahydrofolate (5-MTHF), has been recently gain-
ing considerable attention due to its positive role in cardi-
ovascular disease, neurodegenerative disorders, neural
tube defects, and cancer. Folic acid plays an important
role in the remethylation (methionine – folate cycle) of
homocysteine and is thus capable of lowering elevated
levels of homocysteine [76].
Deficiency or impairment of folate metabolism is associ-
ated with HHcy, hypomethylation (the decreased one car-
bon unit transfer to purines and pyrimidines for DNA
repair and biosynthesis), DNA damage, and impaired cell
proliferation, malignancies, and impaired eNO produc-
tion [47,77-80].
Homocysteine is a competitive inhibitor of PPAR agonists Figure 5
Homocysteine is a competitive inhibitor of PPAR agonists Hcy has recently been found to be a competitive inhibitor 
of the nuclear transcription factors: Peroxisome proliferator activated receptors (PPARs) alpha and gamma. Hcy acts as a lig-
and for the PPAR receptors alpha and gamma and therefore competes with the PPAR alpha ligand: ciprofibrate and the PPAR 
gamma ligand: 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ2). These findings have definite clinical applications, in that; if 
Hcy is not treated to optimal goals the thiazolidinediones (TZDs) may not have their maximal effect on the PPAR receptor.
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5-MTHF is an electron donor, a hydrogen donor, and a
methyl donor [52] and this attribute confers a unique role
to its function. In regards to the eNOS reaction, it supplies
both hydrogen and electrons to the oxidatively modified
tetrahydrobiopterin (BH4): BH2 and BH3. Once biopt-
erin is completely reduced to BH4 (the necessary cofactor
for the eNOS reaction), the eNOS reaction can re-couple
and restore the capability of this reaction to be once again
a net producer of eNO instead of superoxide. This unique
function of folic acid can restore endothelial dependent
vasodilatation in T2DM and hyperlipidemia [81].
Folic acid supplementation would supply the methyl
donating substrate to run the methionine-folate cycle, as
well as, supply the hydrogen and electrons to stabilize the
requisite BH4 cofactor to run the eNOS reaction resulting
in the production of eNO by the endothelium. The resto-
ration of the eNOS reaction, by folate supplementation,
has been demonstrated acutely by flow mediated dilation
studies in T2DM and coronary artery disease via mecha-
nisms, which are largely independent of Hcy lowering
[82,83].
We hypothesize that there may exist a folate shuttle,
which is operative in the atheroscleropathy associated
with MS, PD, and T2DM, as well as, non-diabetic athero-
sclerosis. This folate shuttle effect may operate as an effec-
tive mechanism in the endothelial microenvironment to
recouple the oxidatively stressed, uncoupled, and dys-
functional eNOS reaction (figures 1).
There are three critical arms associated with the eNOS
reaction: the eNOS enzyme, the L-arginine substrate, and
the BH4 cofactor. Each of these three arms is crucial and
has been discussed in previous publications
[31,32,52,84]. The eNOS reaction may be uncoupled due
to oxidative-redox stress associated with MS, PD, T2DM,
atheroscleropathy, and non-diabetic atherosclerosis.
When the eNOS reaction is uncoupled the reaction will
become a net producer of superoxide (instead of eNO via
the eNOS reaction) through the reaction of membranous
NAD(P)H, oxygen, and the NAD(P)H Oxidase enzyme
(figure 6).
The following eNOS reaction demonstrates the location
of the vulnerable three arms of the eNOS reaction respon-
sible for the generation of eNO (figure 6).
If the eNOS reaction is uncoupled: there is the net pro-
duction of superoxide instead of eNO.
The healthy endothelium is a net producer of endothe-
lial nitric oxide [eNO].
The activated – dysfunctional – uncoupled endothe-
lium is a net producer of superoxide [O2
•] associated
with MS, PD, T2DM, and atheroscleropathy.
The net production of superoxide by the uncoupled eNOS
reaction in addition to the production of ROS via the A-
FLIGHT metabolic toxicities results in an excessive oxida-
tive-redox stress.
This oxidant stress may contribute to the oxidation of BH4
to BH2 and BH3, which will be unable to run the eNOS
reaction. Folate supplementation as a methyl donor, a
hydrogen donor, and an electron donor may restore the
oxidized BH2 and BH3 to the requisite completely
reduced BH4 by donating hydrogen and an electron to
BH2 and BH3. With the restoration of BH4, the eNOS
reaction may recouple and once again run the eNOS reac-
tion in order be a net producer of eNO.
As folate is being shared, stolen, shunted, or shuttled from
the remethylation methionine-folate cycle to the eNOS
reaction there will develop a relative endogenous
endothelial folate deficiency with ensuing intra endothe-
lial Hcy accumulation.
The HHcy that results will then play its own additive auto-
oxidative role in the continuing viscous cycle of oxidative
stress to the endothelial microenvironment discussed
previously.
If this endothelial folate shuttle does exist, then one might
assume that Hcy could be a marker of underlying
endothelial oxidative – redox stress in addition to being a
risk factor. The importance of HHcy being a dual risk (a
risk marker and a risk factor) in this patient population
certainly points to its importance in being both a result of
oxidative -redox stress and its important causative role in
endothelial dysfunction.
The importance of the endothelial cell lacking the CBS
enzyme only contributes to the hypothesis of an
endothelial folate shuttle. Even if measured plasma folate
and Hcy levels are normal there may exist a relative
endogenous endothelial folate deficiency within the
endothelial microenvironment due to the folate shuttle
phenomenon.
1
2 () → 
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Cobalamin (vitamin B12)
HHcy is a sensitive marker of clinical cobalamin (the
water soluble vitamin B12) deficiency [85,86]. Folate forti-
fication as well as a more widespread use of folate supple-
ments will have an effect in reducing the frequency of
folate deficiency and cobalamin deficiency may be ranked
above folate deficiency as a primary modifiable cause of
HHcy [87-89].
Common causes of cobalamin deficiency are malabsorp-
tion as a result of (i). lack or dysfunction of gastric intrin-
sic factor (ii). hypochlorhydria as a result of chronic
gastritis, gastric atrophy, or the use of proton pump
inhibitors (iii). the clinical syndromes of inflammatory
bowel disease and celiac disease.
It is of interest to note that one of our newer medications
in our treatment armamentarium for MS, PD, and T2DM
is emerging as a common cause of cobalamin malabsorp-
tion. Metformin use has recently skyrocketed as a popular
treatment for the metabolic derangements associated with
MS, PD, and T2DM. This more novel, yet increasingly,
common cause of cobalamin deficiency in adults and
teenager necessitates a careful approach for the clinician.
Currently, in patients with vitamin B12 deficiency or evi-
dence of peripheral neuropathy or macrocytic anemia the
use of metformin should always be considered in the dif-
Uncoupling of the eNOS reaction Figure 6
Uncoupling of the eNOS reaction This figure demonstrates the three vulnerable arms of the plasma membrane bound 
eNOS reaction responsible for the production of the omnipotent endothelial nitric oxide. Oxygen reacts with the eNOS 
enzyme in which the essential BH4 cofactor has coupled NAD(P)H with L-arginine to be converted to eNO and L-citrulline. If 
uncoupled due to oxidative – redox stress with the essential BH4 cofactor now in the BH2 or BH3 oxidized state the reaction 
will become one of superoxide production adding to the oxidative – redox stress within the endothelial microenvironment. 
The healthy endothelium is a net producer of eNO, whereas, the dysfunctional endothelium becomes a net producer of super-
oxide. It is in this situation that the stabilization of the essential BH4 cofactor (preventing oxidation to BH4) by adequate sup-
plementation of folate becomes so very important.
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ferential diagnosis of B12 malabsorption [90]. A strong
consideration for patient screening of megaloblastic
anemia and or B12 levels in patients on long-term use of
metformin should be considered [91].
Folate fortification and supplementation may mask the
megaloblastic anemia associated with cobalamin defi-
ciency, while allowing the neurological manifestations of
pernicious anemia (peripheral neuropathy, cognitive dis-
turbances, dementia, and depression) to progress. There-
fore it is imperative that cobalamin deficiency be
aggressively sought out and treated, especially in the eld-
erly. In the United States there are 37 million people over
the age of 65 with conservative estimates indicating a two
to three percent (1.1 million) prevalence either having or
will develop pernicious anemia.
Additionally, there are estimated to be 20–30 percent (7.4
– 11.1 million) of this population having subclinical
cobalamin – B12 deficiency, which may lead to HHcy
[87].
Flynn and colleagues [88] were able to demonstrate in
their Longitudinal Aging Study [75] that B12 supplementa-
tion (100 microgram by mouth daily) was effective (P
value 0.0067) in alleviating HHcy in those patients with a
baseline B12 level < 350.
In a meta-analysis of Hcy–lowering studies, folic acid by
mouth (0.5–5 mg daily) resulted in a reduction of Hcy by
25% (P < 0.001). The addition of 0.5 mg vitamin B12 by
mouth daily reduced the Hcy levels by another 3% to 10%
over the reduction with folic acid alone. It was interesting
to note that the addition of 16.5 mg vitamin B6 daily pro-
duced no significant supplemental reducing effect on
blood Hcy levels [89,92,93].
Conclusion
The multiple metabolic A-FLIGHT toxicities (table 4)
observed in MS, PD, T2DM, and atheroscleropathy are
associated with an increase in ROS production. These ROS
result in an increase in oxidative-redox stress and contrib-
ute to the uncoupling of the eNOS reaction and endothe-
lial cell dysfunction.
When accessing the role of the dual risk of HHcy, one has
to be aware of the synergistic effects of ROS produced by
the other multiple toxicities of the A-FLIGHT acronym
and their contributing role of oxidative-redox stress to the
endothelium. This points to the important concept of glo-
bal risk reduction when dealing with MS, PD, T2DM, and
atheroscleropathy.
The current controversy of HHcy being a marker of risk or
a risk factor (important in causation) is not as important
as understanding its overall role in the association with
endothelial cell damage, dysfunction, and a decrease in
eNO bioavailability and how it interacts with other ROS.
The importance of a possible endothelial folate shuttle
points to the important role of folate supplementation in
these at risk patients in order to recouple the eNOS reac-
tion and increase eNO production in addition to its
remethylation properties in the methionine-folate cycle
resulting in lowering of Hcy.
Recently we have become aware of the important role of
highly sensitive C reactive protein (hsCRP) and the role of
inflammation in the development and progression of car-
diovascular disease, MS, PD, and T2DM [94-98]. It has
been interesting to watch the hsCRP story unfold and
since oxidative – redox stress occurs upstream from the
inflammatory cycle via the activation of NFkappa B it
seems so very important to better understand the role of
HHcy and how it interacts with the ROS produced by the
other metabolic toxicities of the A-FLIGHT acronym (fig-
ure 4).
Dietary folate supplementation is extremely important for
proper endothelial cell health maintenance and function.
A simplified overview of the positive roles of folate sup-
plementation include the following [99]:
I. Folate is a methyl donor. Important in lowering the
toxic Hcy elevation. Hcy elevation may be a marker of
folate deficiency or dysfunction.
II. Folate is a hydrogen donor. Important in maintaining
and stabilizing the essential tetrahydrobiopterin (BH4)
Cofactor of the eNOS enzyme reaction to prevent
uncoupling.
III. Folate is an electron donor. Important as an antioxi-
dant to reduce oxidative – redox stress. Important as a
chain breaking antioxidant. Stabilizing the eNOS reaction
and protecting the generation of eNO.
Numbers II and III could be thought of as pleiotropic
effects: The effects of folate supplementation independent
of Hcy lowering, which play a significant role in the stabi-
lization of the eNOS reaction and production of eNO as
discussed in the section regarding the FOLATE SHUTTLE
phenomenon.
Therefore, in addition to nutritional – dietary folate intake
[100], pharmacological folate supplementation should
now be strongly considered as part of the clinical global
risk reduction treatment paradigm for those at risk
patients with MS, PD, T2DM, and atheroscleropathy.Nutrition Journal 2004, 3 http://www.nutritionj.com/content/3/1/4
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Controversy exists as to who should be screened and who
should be treated. The following questions are
appropriate:
Should we do not test and do not treat?
Should we treat all patients because it makes good clinical
sense and therapy is inexpensive?
Should we screen patients with established atherosclerotic
and venous thromboembolic disease and high-risk
patients with MS, T2DM, and atheroscleropathy and initi-
ate therapy if Hcy is at or above the 9–15 micromol/L
range?
The later is preferred and it may be suggested that the cur-
rent treatment guidelines for the treatment of HHcy
should be one of cardiovascular global risk reduction
(table 9) of oxidative – redox stress and reactive oxygen
species generated from the multiple metabolic toxicities
(table 4). In addition to global risk reduction, current sug-
gested guidelines for the treatment of HHcy as a result of
this review are presented in (table 10) [101].
The significance of proper nutrition is of paramount
importance; however, once moderate to severe HHcy is
identified, existing concepts indicate that diet alone is
insufficient to normalize Hcy levels in many patients.
This brief review has attempted to provide the reader with
a database of knowledge regarding the current role of Hcy
and how it interacts with the MS, T2DM, and atheroscle-
ropathy. For those interested in a more in depth review
consideration should be given to review the new Journal:
METABOLIC SYNDROME AND RELATED DISORDERS.
Volume 1 number 2 has been dedicated to homocysteine
and the metabolic syndrome [102-110].
Soinio M et al. have just published an exciting article
involving a large cohort of patients (462 men and 368
women in the age group of 45–64 years of age at baseline)
with T2DM. They were able to demonstrate that plasma
Hcy was a strong and independent risk factor for CHD
events. Even though impaired renal function is associated
with higher plasma Hcy concentrations, this group was
able to show that the association between elevated plasma
Hcy level and high incidence of CHD events did not
depend on renal function [111].
The damaging – toxic role of Hcy in the vascular bed has
been well documented in the medical literature and its
diffuse role not only in MS, T2DM, and atheroscleropathy
but also in multiorgan damage is emerging [80] (figure 7).
To summarize, HHcy in the general population is an inde-
pendent risk factor for cardiovascular disease as occurs in
thrombotic events (such as arterial and venous occlusion)
and ischemic disease such as stroke and myocardial inf-
arction (two of the most common causes of death and dis-
Table 9: THE RAAS ACRONYM: GLOBAL RISK REDUCTION
R Reductase inhibitors (HMG-CoA). Decreasing modified LDL-cholesterol, i.e. oxidized, acetylated LDL-cholesterol. Decreasing 
triglycerides and increasing HDL-cholesterol Improving endothelial cell dysfunction. Restoring the abnormal Lipoprotein fractions. Thus, 
decreasing the redox and oxidative stress to the arterial vessel wall and myocardium. Redox stress reduction.
A AngII inhibition or blockade: ACEi-prils. ARBS-sartans. Both inhibiting the effect of angiotensin-II locally as well as systemically. 
Affecting hemodynamic stress through their antihypertensive effect as well as the deleterious effects of angiotensin II on cells at the local 
level – injurious stimuli -decreasing the stimulus for O2
• production. Decreasing the A-FLIGHT toxicities. Plus the direct-indirect 
antioxidant effect within the arterial vessel wall and capillary.
Antioxidant effects.
Aspirin antiplatelet, anti-inflammatory effect.
Adrenergic (non-selective blockade) in addition to its blockade of Prorenin → Renin
Amlodipine with its calcium channel blocking antihypertensive effect, in addition to its direct antioxidant effects. Redox stress 
reduction.
A Aggressive control of diabetes to HbA1c of less than 7. (This usually requires combination therapy with the use of: Insulin secretagogues, 
insulin sensitizers (thiazolidinediones), biguanides, alpha-glucosidase inhibitors, and ultimately exogenous insulin.) [36-38]
Decreasing modified LDL cholesterol, i.e. glycated – glycoxidated LDL cholesterol. Improving endothelial cell dysfunction. Also decreasing 
glucotoxicity and the oxidative – redox stress to the intima and pancreatic islet.
Aggressive control of blood pressure, which usually requires combination therapy, including thiazide diuretics to attain JNC 7 guidelines.
Aggressive control of Hcy with folic acid and its associated pleiotropic positive effect on re-coupling the eNOS reaction by restoring the 
activity of the BH4 cofactor to run the eNOS reaction and once again produce eNO, as well as, its direct antioxidant effects: BH4 and 
eNOS stabilization Redox stress reduction.
S Statins. Improving plaque stability (pleiotropic effects) independent of cholesterol lowering. Improving endothelial cell dysfunction. Plus, 
the direct – indirect antioxidant anti-inflammatory effects within the islet and the arterial vessel wall promoting stabilization of the 
unstable, vulnerable islet and the arterial vessel wall.
Style: Lifestyle modification: lose weight, exercise, and change eating habits. Stop Smoking Redox stress reductionNutrition Journal 2004, 3 http://www.nutritionj.com/content/3/1/4
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ability). With an aging population who are at greater risk
of developing these morbid and mortal cardiovascular
diseases associated with MS, T2DM, and atheroscleropa-
thy, there should exist a dedicated consideration for folate
and possible cobalamin supplementation, in addition too
global risk reduction.
Abbreviations
Ang II: angiotensin II; RAAS renin angiotensin aldoster-
one system; ROS: reactive oxygen species (O2
•, -OH•,
H2O2, 1O2); AT-1 angiotensin type one receptor; PKC:
protein kinase C; IAPP: islet amyloid polypeptide; TGF-
beta –1: transforming growth factor beta- 1; NAD(P)H
oxidase: nicotine adenine di nucleotide phosphate oxi-
dase reduced; AGE: advanced glycation endproducts; AFE:
advanced fructosylation endproducts; RAGE: receptor for
advanced glycosylation endproducts; ALE: advanced
lipoxidation endproducts; eNOS: Endothelial Nitric
Oxide Synthase; NO: nitric oxide; BH4: tetra hydro
biopterin; FFA: free fatty acids; LC acyl –CoA's: long chain
acyl Co enzyme A; VLDL: Very low density lipoprotein;
LDL: low density lipoprotein; HDL: high density lipopro-
tein; MS: Metabolic Syndrome; PD: prediabetes; T2DM:
type 2 diabetes mellitus; PAI-1: plasminogen activator
inhibitor –1; H2O: water; Glut-4: glucose transporter-4;
PI3 Kinase: phosotidyl inositol 3 kinase; Akt: protein
kinase B; MAP Kinase: mitogen activated protein Kinase;
MAP Kinase Shunt: The shunting away from the positive
Glut 4 PI3 Kinase Akt pathway to the deleterious MAP
Kinase pathway promoting remodeling due to an altera-
tion in the NO redox sensitive PI3 Kinase /Akt pathway;
IL-6 IL-8: interleukin-6 interleukin-8; TNF alpha: tumor
necrosis factor alpha; MPO: myeloperoxidase: Generation
of Superoxide (O2
•) via hypochlorous acid HClO-; NF
kappa B: nuclear factor kappa B; ICAM: inter cellular
adhesion molecule; VCAM: vascular cellular adhesion
molecule; MCP-1: monocyte chemoattractant protein-1;
NADH: nicotinamide adenine dinucleotide reduced;
NAD+: nicotinamide adenine dinucleotide oxidized;
DAG: diacylglycerol; GPx: glutathione peroxidase; DDAH:
dimethylarginine dimethylaminohydrolase; ADMA:
asymmetrical dimethyl arginine; O2
• – ONOO• : superox-
ide – peroxynitrite.
Table 10: SUGGESTEDTREATMENT GUIDELINES FOR HHcy
Fasting plasma total Hcy (tHcy) levels:
The prevalence of HHcy in the general population is between five and ten 
percent (using a threshold set at the 90th to 95th percentile of 15 micromol / 
liter). Keep in mind that this figure may escalate to, as high as, 30% to 40 % in 
the elderly.
Normal: 5–15 micromol/L (Based on table below 5 – 9 micromol/L)
Moderate: 15–30 micromol/L
Intermediate: 31–100 micromol/L
Severe: >100 micromol/L
Goal of Treatment: 9 micromol / Liter or less. (Based on table below)
HYPERHOMOCYSTEINEMIA
Check for secondary causes:
Renal dysfunction
Folate B12 B6 deficiency * Significant to exclude Pernicious Anemia
Hypothyroidism and others (table 2)
GLOBAL RISK REDUCTION (table 9)
1. Diet rich in B vitamins and folate [IF NOT TO GOAL]
2. Advance to multivitamin therapy 400 microgram folic acid, 2 mg B6, and 6 
mg B12. [IF NOT TO GOAL]
3. Advance to prescription strength 1 mg folic acid, 25 mg B6, and 500 
microgram B12. [IF NOT TO GOAL]
4. Advance to 2–5 mg folic acid, B12 to 1,000 microgram, and B6 25 – 100 mg.
5. Sublingual and injectable B12 may be used if necessary, as well as, a trial of 
Betaine hydrocloride in intractable cases. Higher doses of up to 15 mg of folic 
acid may be required in hemodialysis patients.
6. Global Risk Reduction (table 9)
Consider: Total Hcy is associated with a graded mortality risk. Patients with 
known CAD have the following graded risk [95,97]:
tHCY in micromol/liter Relative risk of all cause death. Relative risk of CAD death
< 9 1.0 1.0
9 – 14.9 1.9 (0.7 – 5.1) 2.3 (0.7 – 7.7)
15 – 19.9 2.8 (0.9 – 9.0) 2.5 (0.6 – 10.5)
> 20 4.5 (1.2 – 16.6) 7.8 (1.7 – 35.1)Nutrition Journal 2004, 3 http://www.nutritionj.com/content/3/1/4
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The homocysteine wheel: multiorgan damage through redox stress Figure 7
The homocysteine wheel: multiorgan damage through redox stress Homocysteine is capable of causing multi-organ 
damage through the process of oxidative – redox stress. The endothelium is very vulnerable to the effects of HHcy because 
the endothelium lacks the CBS enzyme, which results in the local loss of the important catabolic metabolism of Hcy. While this 
article has focused on the cardiovascular manifestations associated with MS, PD, and T2DM there exists numerous other organ 
systems and diseases associated with the damaging effects of HHcy.Nutrition Journal 2004, 3 http://www.nutritionj.com/content/3/1/4
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